Pancreatic Cancer Research

ResearcherJilin UniversityActive in the last 2 years

Shengnan Jia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5673-7744; OpenAlex author ID A5086184972. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: 4 papers · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 16

  1. Using Machine Learning Methods to Develop Diagnostic and Prognostic mRNA Signatures for Pancreatic Cancer in Plasma Small Extracellular Vesicles. First author DOI 10.1007/s10620-025-08867-6↗
  2. Proteomic Characterization of Urinary Exosomes with Pancreatic Cancer by Phosphatidylserine Imprinted Polymer Enrichment and Mass Spectrometry Analysis. Co-author DOI 10.1021/acs.jproteome.4c00508↗
  3. Correction: Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Co-author DOI 10.1038/s41419-023-06399-3↗
  4. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Last author DOI 10.1186/s13578-023-01118-z↗
  5. Scaffold-based three-dimensional cell model of pancreatic cancer is more suitable than scaffold-free three-dimensional cell model of pancreatic cancer for drug… First author DOI 10.1007/s10616-022-00553-z↗
  6. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.013↗
  7. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Co-author DOI 10.1038/s41419-020-03019-2↗
  8. Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanopartic… Co-author DOI 10.3892/ol.2020.11302↗
  9. The distinct role of CD73 in the progression of pancreatic cancer. First author DOI 10.1007/s00109-018-01742-0↗
  10. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Co-author DOI 10.1038/s41419-019-1366-y↗
  11. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. First author DOI 10.7150/jca.31191↗
  12. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. Co-author DOI 10.1089/jir.2018.0070↗
  13. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. Co-author DOI 10.7150/jca.21046↗
  14. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.21683↗
  15. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. Co-author DOI 10.7150/jca.21749↗
  16. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08479-9↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liping Cao · 13 shared papers, 2017–2023 · strength 1.54
  2. Guoping Ding · 12 shared papers, 2018–2024 · strength 1.52
  3. Xiaodong Xu · 5 shared papers, 2018–2024 · strength 0.75
  4. Liangjing Zhou · 7 shared papers, 2017–2022 · strength 0.70
  5. Liping Cao · 2 shared papers, 2024–2025 · strength 0.68
  6. Zhen Liu · 1 shared paper, 2025 · strength 0.42
  7. Dongnan Ping · 2 shared papers, 2020–2022 · strength 0.32
  8. Xianhui Cheng · 1 shared paper, 2025 · strength 0.30
  9. Lianghai Hu · 1 shared paper, 2025 · strength 0.30
  10. Mingjie Zhang · 3 shared papers, 2018–2019 · strength 0.29
  11. Zhengrong Wu · 2 shared papers, 2019 · strength 0.20
  12. Weihua Yu · 2 shared papers, 2019 · strength 0.20
  13. Dafei Xie · 1 shared paper, 2022 · strength 0.20
  14. Guixing Jiang · 2 shared papers, 2018 · strength 0.18
  15. Jionghuang Chen · 2 shared papers, 2018 · strength 0.18
  16. Yimin Ding · 1 shared paper, 2023 · strength 0.18
  17. Chaojie Huang · 1 shared paper, 2022 · strength 0.15
  18. Tianshu Pang · 1 shared paper, 2022 · strength 0.15
  19. Chaolei Zhang · 1 shared paper, 2022 · strength 0.15
  20. Xiaofan Pu · 1 shared paper, 2020 · strength 0.13
  21. Dan Li · 1 shared paper, 2020 · strength 0.12
  22. Ting Zhao · 1 shared paper, 2018 · strength 0.09
  23. Tao Shen · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.